Rumsfield J A, West D P, Tse C S, Eaton M L, Robinson L A
Drug Intell Clin Pharm. 1983 May;17(5):329-33. doi: 10.1177/106002808301700502.
Isotretinoin, an isomer of retinoic acid, recently has been approved by the Food and Drug Administration for treatment of severe, recalcitrant acne. The most impressive effects include inhibition of sebum production and a reversible decrease in sebaceous gland size. Isotretinoin has proved to be an effective drug; response to therapy has been seen in virtually 100 percent of patients treated. Almost all patients experience reversible cutaneous and mucous-membrane symptoms while on isotretinoin treatment. Other common side effects include conjunctivitis (38 percent) and eye irritation (50 percent). The recommended dosage is 1-2 mg/kg/d for no longer than 16 weeks. Isotretinoin is currently the treatment of choice for severe, recalcitrant acne; however, because of potential side effects associated with retinoids, isotretinoin should be reserved for those patients who are unresponsive to conventional therapy, including topical and systemic antibiotics.
异维A酸是维甲酸的一种异构体，最近已获美国食品药品监督管理局批准用于治疗重度、难治性痤疮。其最显著的效果包括抑制皮脂分泌以及皮脂腺大小的可逆性减小。异维A酸已被证明是一种有效的药物；几乎100%接受治疗的患者都对治疗有反应。几乎所有患者在接受异维A酸治疗时都会出现可逆的皮肤和黏膜症状。其他常见副作用包括结膜炎（38%）和眼部刺激（50%）。推荐剂量为1 - 2毫克/千克/天，疗程不超过16周。异维A酸目前是重度、难治性痤疮的首选治疗药物；然而，由于与维甲酸相关的潜在副作用，异维A酸应仅用于那些对包括局部和全身抗生素在内的传统治疗无反应的患者。
